Journal of Cancer Research and Clinical Oncology

, Volume 131, Issue 4, pp 255–260

Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer

  • J. Wierecky
  • C. Kollmannsberger
  • I. Boehlke
  • M. Kuczyk
  • J. Schleicher
  • N. Schleucher
  • B. Metzner
  • L. Kanz
  • J. T. Hartmann
  • C. Bokemeyer
Original Paper



We investigated the incidence of secondary leukemia in patients treated with first-line high-dose chemotherapy (HDCT) plus autologous stem cell transplantation (PBSCT) for advanced testicular cancer.


Three hundred and twenty-three patients who were entered into two consecutive prospective Phase-II studies of the German Testicular Cancer Study Group were analyzed. A total of 221 patients had received HD-VIP containing cisplatin, ifosfamide, and etoposide and 102 patients were treated with Tax-HD-VIP containing cisplatin, ifosfamide, etoposide, and paclitaxel, each cycle supported by autologous PBSCT.


Patients had received a median cumulative etoposide dose of 4.9 g/m2 (range, 2.2–9.4 g/m2). The median follow-up duration for all patients was 36 months (range, 0–128) with a median follow up time of 50 months (range, 0–128) for patients surviving at least 1 year after therapy. One patient developed a secondary acute myeloid leukemia (s-AML) involving a chromosomal translocation t(11;19)(q23;p13.3) 24 months after the start of chemotherapy resulting in a cumulative incidence of 0.48% [95% confidence interval (CI) 0–1.42]. Additionally, two patients with primary mediastinal germ cell cancer developed a myelodysplastic syndrome. No solid tumors had occurred.


HDCT including high-dose etoposide with autologous PBSCT as first-line therapy for advanced testicular cancer was associated with an acceptably low risk of developing secondary leukemia.


Secondary leukemia High-dose chemotherapy Etoposide Germ cell cancer 


  1. 1.
    Bajorin DF, Motzer RJ, Rodriguez E, Murphy B, Bosl GJ (1993) Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 85:60–62PubMedGoogle Scholar
  2. 2.
    Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S, Greco FA (1986) Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400–407PubMedGoogle Scholar
  3. 3.
    Bokemeyer C, Schmoll H-J (1993) Secondary neoplasms following treatment of malignant germ-cell tumors. J Clin Oncol 11:1703–1709PubMedGoogle Scholar
  4. 4.
    Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Nat Cancer Inst 87:58–60Google Scholar
  5. 5.
    Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17:3450–3456PubMedGoogle Scholar
  6. 6.
    Boshoff C, Begent RH, Oliver RT, Rustin GJ, Newlands ES, Andrews R, Skelton M, Holden L, Ong J (1995) Secondary tumors following etoposide containing therapy for germ cell cancer. Ann Oncol 6:35–40PubMedGoogle Scholar
  7. 7.
    Bosl GJ, Motzer RJ (1997) Medical progress: testicular germ cell cancer. N Engl J Med 337:242–253PubMedGoogle Scholar
  8. 8.
    Chevreau C, Droz JP, Pico JL, Biron P, Kerbrat P, Cure H, Heron JF, Chevallier B, Fargeot P, Kramar A (1993) Early intensified chemotherapy with autologous bone marrow transplantation in first-line treatment of poor risk nonseminomatous germ cell tumors. Prelimanary results of a French randomized trial. Eur Urol 23:213–217PubMedGoogle Scholar
  9. 9.
    Decatris MP, Wilkinson PM, Welch RS, Metzner M, Morgenstern GR, Dougall M (2000) High-dose chemotherapy and autologous hematopoietic support in poor risk non-seminomatous germ-cell tumors: an effective first-line therapy with minimal toxicity. Ann Oncol 11:427–434PubMedGoogle Scholar
  10. 10.
    Felix CA (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors. Med Pediatr Oncol 36:525–535Google Scholar
  11. 11.
    Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Fizazi K, Einhorn L, Kanz L, Bokemeyer C (2000) Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst 92:54–61PubMedGoogle Scholar
  12. 12.
    Hartmann JT, Schleucher N, Metzner B, Koehne CH, Gerl A, Schleicher J, Rick O, Derigs HG, Beyer J, Boehlke I, Kanz L, Bokemeyer C (2001) Phase I/II study of sequential high dose VIP plus paclitaxel in patients with “poor prognosis” germ cell tumor. Proc Am Soc Clin Oncol 24 [abstr 691]Google Scholar
  13. 13.
    Houck W, Abonour R, Vance G, Einhorn LH (2003) Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J Clin Oncol 22:2155–2158CrossRefGoogle Scholar
  14. 14.
    International Germ Cell Cancer Collaborative Group (1997) International Germ Cell Cancer Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15:594–603PubMedGoogle Scholar
  15. 15.
    Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Fléchon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C (1998a) Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ-cell tumors. J Clin Oncol 16:3386–3391PubMedGoogle Scholar
  16. 16.
    Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C (1998b) Risk of secondary leukemia and myelodysplastic syndrome following standard dose chemotherapy or high dose chemotherapy with stemm cell support in patients with potentially curable malignancies. J Cancer Res Clin Onc 124:207–214Google Scholar
  17. 17.
    Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C (1999) Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 83:860–863PubMedGoogle Scholar
  18. 18.
    Le Delay MC, Leblanc T, Shamsaldin A, Raquin MA, Lacour B, Sommelet D, Chompret A, Cayuela JM, Bayle C, Bernheim A, de Vathaire F, Vassal G, Hill C (2003) Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d’Oncologie Pediatrique. J Clin Oncol 21:1074–1081PubMedGoogle Scholar
  19. 19.
    Margolin BK, Doroshow JH, Ahn C, Hamasaki V, Leong L, Morgan R, Raschko J, Shibata S, Somlo G, Tetef M (1996) Treatment of germ cell cancer with two cycle of high-dose ifosfamide, carboplatin and etoposide with autologous stem-cell support. J Clin Oncol 14:2631–2637PubMedGoogle Scholar
  20. 20.
    Micallef IN, Lillington DM, Apostolidis J, Amess JA, Neat M, Matthews J, Clark T, Foran JM, Salam A, Lister TA, Rohatiner AZ (2000) Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18:947–55PubMedGoogle Scholar
  21. 21.
    Motzer RJ, Mazumdar M, Gulati SC, Bajorin DF, Lyn P, Vlamis V, Bosl GJ (1993) Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor risk germ cell tumors. J Natl Cancer Inst 85:1828–1835PubMedGoogle Scholar
  22. 22.
    Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V (1997) High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor risk germ cell tumors. J Clin Oncol 15:2546–2552PubMedGoogle Scholar
  23. 23.
    Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, Akard L, Hoffman R, Goulet R, Wolff SN (1989) Dose-intensive chemotherapy in refractory germ cell cancer- a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932–939PubMedGoogle Scholar
  24. 24.
    Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G (1990) Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 322:1425–1429PubMedGoogle Scholar
  25. 25.
    Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K (1990) Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083–1091PubMedGoogle Scholar
  26. 26.
    Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M (1991) Increased risk of myelodysplasia and leukemia after etoposide, cisplatin and bleomycin for germ cell tumors. Lancet 338:359–363PubMedGoogle Scholar
  27. 27.
    Pui CH, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, Head DR, Behm FG, Mahmoud MH, Sandlund JT (1991) Acute myeloid leukemia in children treated with epipodopyllotoxins for acute lymphoblastic leukemia. N Engl J Med 325:1682–1687PubMedGoogle Scholar
  28. 28.
    Roth BJ, Greist A, Kubilis PS, Williams SD, Einhorn LH (1988) Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long term follow-up. J Clin Oncol 6:1239–1247PubMedGoogle Scholar
  29. 29.
    Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German testicular cancer study group. J Clin Oncol 21:4083–4091CrossRefPubMedGoogle Scholar
  30. 30.
    Schneider DT, Hilgenfeld E, Schwabe D, Behnisch W, Zoubek A, Wessalowski R, Gobel U (1999) Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. J Clin Oncol 17:3226–3233PubMedGoogle Scholar
  31. 31.
    Seymour JF, Juneja SK, Campbell LJ, Ellims PH, Estey EH, Prince HM (1999) Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia 13:1735–40Google Scholar
  32. 32.
    Sonneveld DJ, Hoekstra HJ, van der Graaf WT, Sluiter WJ, Mulder NH, Willemse PH, Koops HS, Sleijfer DT (2001) Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91:1304–1315PubMedGoogle Scholar
  33. 33.
    Thirman MJ, Larson RA (1996) Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 10:293–320PubMedGoogle Scholar
  34. 34.
    van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EH, Delemarre JF, Somers R (1993) Second cancer risk following testicular cancer: a follow up study of 1909 patients. J Clin Oncol 11:415–424PubMedGoogle Scholar
  35. 35.
    Whitlock J, Greer J, Lukens J (1991) Epipodophyllotoxin-related leukemia. Cancer 68:600–604PubMedGoogle Scholar
  36. 36.
    Wierecky J, Kollmannsberger C, Boehlke I, Kuczyk M, Schleicher J, Schleucher N, Metzner B, Kanz L, Hartmann JT, Bokemeyer C (2005) Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol (this issue)Google Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • J. Wierecky
    • 1
  • C. Kollmannsberger
    • 1
  • I. Boehlke
    • 1
  • M. Kuczyk
    • 2
  • J. Schleicher
    • 3
  • N. Schleucher
    • 4
  • B. Metzner
    • 5
  • L. Kanz
    • 1
  • J. T. Hartmann
    • 1
  • C. Bokemeyer
    • 1
  1. 1.Department of Oncology, Hematology, Immunology, and Rheumatology, Medizinische KlinikUniversity of Tuebingen Medical CenterTuebingenGermany
  2. 2.Department of UrologyUniversity of Tuebingen Medical CenterTuebingenGermany
  3. 3.Department of OncologyKatharinenhospitalStuttgartGermany
  4. 4.Department of OncologyWestdeutsches Tumorzentrum EssenEssenGermany
  5. 5.Department of Oncology and HematologyKlinikum OldenburgOldenburgGermany

Personalised recommendations